For Q2 FY26, consolidated volumes rose 16.2% year-on-year to 34.2 lakh cases, with the company recording market share gains in most key markets. Shares of…
Godrej Consumer Products’ latest acquisition marks a major bet on India’s booming men’s grooming and D2C space. With Muuchstac’s founders continuing to run the brand,…
MIDHANI’s Q2 net profit fell 45.6% to ₹12.95 crore, revenue dropped 20%, but its ₹1869 crore order book and rising exports to Boeing, Airbus, and…
EBITDA for the quarter stood at ₹470.6 crore, down 5.8% from ₹499.5 crore in Q2 FY25. However, the company’s operating margin improved to 24.5% from…
Zydus Lifesciences received USFDA approval for its Diroximel Fumarate capsules for multiple sclerosis, while concluding a USFDA inspection at its oncology plant in Ahmedabad with…
The benchmark Nifty50 index continues to encounter a psychological barrier near 26,000, and a breakout above this level is crucial for further upside.
The S&P 500 fell 0.5%, while the tech-heavy Nasdaq Composite dropped 0.9%, as investors moved out of growth and technology stocks into more value-driven sectors.
In the US and North America, Marksans Pharma’s formulation business reported revenues of ₹387.3 crore in Q2 FY26, demonstrating robust performance despite macroeconomic headwinds. Tariff…
The Eternal CEO wrote that his longevity venture Continue’s two-year research has identified ‘one element of our environment’ that could hold the key to extending…
Concord Biotech also reported drops in revenue, EBITDA and margins for Q2FY26. Shares of Concord Biotech Ltd ended marginally higher on Thursday, November 13, up…